Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
iTeos Therapeutics to Present at the 2017 BIO CEO & Investor Conference
Gosselies, Belgium - February 10, 2017 - iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced that Michel Detheux, iTeos' Chief Executive Officer, will present at the 2017 BIO CEO & Investor Conference on Tuesday, February 14 2017 at 10:45 a.m. ET in Park North at The Waldorf Astoria in New York, NY.
If you would like to meet with the iTeos management team, please contact the event organizers or [email protected].
For more information about the 2017 BIO CEO & Investor Conference, please refer to the conference website at: http://ceo.bio.org.
About iTeos Therapeutics S.A.
Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic tumors. It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos' competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit www.iteostherapeutics.com.
Contacts:
Michel Detheux, CEO
iTeos therapeutics
+32 71 919 933
[email protected]
Sarah McCabe
Stern Investor Relations, Inc.
+ 1 212 362-1200
[email protected]
Jonathan Birt, Mathew Neal, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
[email protected]
